Peptides News and Research

RSS

JDRF, Amylin collaborate to support metreleptin study for type 1 diabetes

The Juvenile Diabetes Research Foundation (JDRF) and Amylin Pharmaceuticals, Inc. announced today that they entered into a research collaboration agreement to provide financial support for a clinical proof-of-concept study to investigate the effects of metreleptin, an analog of the human hormone leptin, in patients with type 1 diabetes. Researchers at The University of Texas (UT) Southwestern Medical Center will conduct the study.

17 Nov 2010

Stratatech receives SBIR grant to develop anti-infective living human skin substitute

Stratatech Corp., a privately-held regenerative medicine company, today announced that it has been awarded a $3.5 million Fast-Track SBIR grant to expand the development of its anti-infective living human skin substitute.

17 Nov 2010

Oramed presents ORMD-0801 Phase IIb results for Type II diabetes at Annual Meeting in Bethesda

Oramed Pharmaceuticals Inc., a developer of oral drug delivery systems, presented the results of its recently completed Phase IIb trial. The multicenter, placebo-controlled, randomized, double-blind study conducted in 29 patients with Type II diabetes assessed the safety of ORMD-0801 in patients with Type II diabetes.

16 Nov 2010

Tufts University professor receives NIH Director's New Innovator Award

Joshua Kritzer, assistant professor in the School of Arts and Sciences Department of Chemistry at Tufts University, has been awarded one of 33 NIH Director's New Innovator Awards, one of the most prestigious grants awarded by the National Institutes of Health.

15 Nov 2010

ICON, Proteome enter alliance to provide expanded biomarker solutions

ICON plc, a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, and Proteome Sciences a leading provider of protein biomarker discovery, validation, and assay development services, today announced the formation of a strategic alliance to provide pharmaceutical companies with an expanded biomarker solution to allow earlier assessments in the development of new medicines.

15 Nov 2010

NephRx initiates NX001 Phase I clinical trial to prevent DGF in kidney transplant patients

NephRx Corporation today announced that it has initiated a Phase I clinical trial of its lead compound NX001 and has successfully dosed the first subject in the study. NX001, a kidney growth factor peptide that has demonstrated good safety and promising efficacy in two animal models of acute renal failure, is in development for the prevention of delayed graft function (DGF) in kidney transplantation patients.

11 Nov 2010

Aeterna Zentaris to present AEZS-108 Phase 2 results for endometrial cancer at EORTC-NCI-AACR Symposium

Aeterna Zentaris Inc. today announced that it will present a poster on Phase 2 results for AEZS-108 in advanced endometrial cancer at the 22nd EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics to be held at the Berlin Estrel Hotel and Convention Centre in Berlin, Germany November 16 through 19, 2010.

11 Nov 2010

PolyMedix announces publication of defensin-mimetic compounds in Molecular Oral Microbiology

PolyMedix, Inc. an emerging biotechnology company focused on developing new therapeutic drugs to treat infectious diseases and acute cardiovascular disorders, announced that data from two separate pre-clinical research studies were published in the December issue of Molecular Oral Microbiology.

10 Nov 2010

Antigen Express awarded Therapeutic Discovery Project grants for cancer vaccine development

Generex Biotechnology Corporationannounced today that its wholly-owned immunotherapeutics subsidiary, Antigen Express, Inc. has been awarded two Therapeutic Discovery Project grants, totaling $488,958.50, by the United States Internal Revenue Service (IRS) and the Department of Health and Human Services (HHS) pursuant to the Patient Protection and Affordable Care Act of 2010.

10 Nov 2010

MonoSol Rx granted U.S. patent for PharmFilm and production technologies

MonoSol Rx, the developers of PharmFilm® technology and a drug delivery company specializing in proprietary pharmaceutical film products, today announced that it has been granted U.S. patent No. 7,824,588 from the United States Patent and Trademark Office (USPTO). The patent, issued on November 2, 2010, provides intellectual property protection for the Company's film products and methods of their preparation.

10 Nov 2010

Capstone Therapeutics third quarter net loss decreases to $2.6 million

Capstone Therapeutics, formerly OrthoLogic Corp.,, today announced financial results for the third quarter of 2010.

10 Nov 2010

Discovery Labs reports net operating loss of $6.2 million for third quarter 2010

Discovery Laboratories, Inc., a biotechnology company developing its novel, synthetic, peptide-containing surfactant and related aerosolization technologies as first in class therapies for severe respiratory diseases, today provides an update on key pipeline and business initiatives and a financial update for the third quarter ended September 30, 2010.

9 Nov 2010

Research report on current and evolving technologies in drug delivery

The drug delivery market is a rapidly evolving force in the pharmaceutical industry. Within this segment injectables have a significant role to play at present with the increasing use of proteins and peptides.

9 Nov 2010

Research on immune system may help in healing chronic inflammatory diseases

Biochemists at Kiel University, along with international scientists, have identified an important messenger in the immune system. The messenger interleukin-27 plays an important role when the human body blocks inflammations.

9 Nov 2010

Raptor initiates dosing in DR Cysteamine Phase 2 clinical trial for Huntington's Disease

Raptor Pharmaceutical Corp., today announced that the first patient has been dosed in its Phase 2 clinical trial of DR Cysteamine for the potential treatment of Huntington's Disease. The Phase 2 clinical trial is being conducted under a previously announced collaboration agreement with The Centre Hospitalier Universitaire d'Angers ("CHU d'Angers"), which has commenced enrolling patients at eight clinical sites throughout France.

8 Nov 2010

Anti-TNF therapies may reduce Alzheimer's risk among people with rheumatoid arthritis

Anti-TNF therapies commonly used to treat rheumatoid arthritis have been found to potentially reduce the risk of developing Alzheimer's dementia among people with rheumatoid arthritis, according to research presented this week at the American College of Rheumatology Annual Scientific Meeting in Atlanta.

8 Nov 2010

Early interference in entorhinal cortex may halt progression of Alzheimer's disease

New research is helping to unravel the events that underlie the "spread" of Alzheimer's disease (AD) throughout the brain. The research, published by Cell Press in the November 4th issue of the journal Neuron, follows disease progression from a vulnerable brain region that is affected early in the disease to interconnected brain regions that are affected in later stages. The findings may contribute to design of therapeutic interventions as targeting the brain region where AD originates would be simpler than targeting multiple brain areas.

4 Nov 2010

Scientists identify events that causes AD progression

Scientists at the Gladstone Institute of Neurological Disease (GIND) have offered new information about the events that underlie the "spread" of Alzheimer's disease (AD) throughout the brain.

4 Nov 2010

BioCurex files patent for synthetic peptide in RECAF test

BioCurex, Inc. today announced that it has filed a new patent within the Patent Cooperation Treaty, which presently includes 142 countries.

4 Nov 2010

Immunomedics product candidates, technologies receive recognition from QTDP program

Immunomedics, Inc. a biopharmaceutical company primarily focused on the development of monoclonal, antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases, today announced that all 12 applications from the Company were certified by the Internal Revenue Service of the Department of Treasury as qualified investments in accordance with the Qualifying Therapeutic Discovery Project (QTDP) program under section 48D of the Internal Revenue Code. As a result, the Company will receive an aggregate cash award of $2.9 million.

3 Nov 2010

Peptides News and Research

JDRF, Amylin collaborate to support metreleptin study for type 1 diabetes

Stratatech receives SBIR grant to develop anti-infective living human skin substitute

Oramed presents ORMD-0801 Phase IIb results for Type II diabetes at Annual Meeting in Bethesda

Tufts University professor receives NIH Director's New Innovator Award

ICON, Proteome enter alliance to provide expanded biomarker solutions

NephRx initiates NX001 Phase I clinical trial to prevent DGF in kidney transplant patients

Aeterna Zentaris to present AEZS-108 Phase 2 results for endometrial cancer at EORTC-NCI-AACR Symposium

PolyMedix announces publication of defensin-mimetic compounds in Molecular Oral Microbiology

Antigen Express awarded Therapeutic Discovery Project grants for cancer vaccine development

MonoSol Rx granted U.S. patent for PharmFilm and production technologies

Capstone Therapeutics third quarter net loss decreases to $2.6 million

Discovery Labs reports net operating loss of $6.2 million for third quarter 2010

Research report on current and evolving technologies in drug delivery

Research on immune system may help in healing chronic inflammatory diseases

Raptor initiates dosing in DR Cysteamine Phase 2 clinical trial for Huntington's Disease

Anti-TNF therapies may reduce Alzheimer's risk among people with rheumatoid arthritis

Early interference in entorhinal cortex may halt progression of Alzheimer's disease

Scientists identify events that causes AD progression

BioCurex files patent for synthetic peptide in RECAF test

Immunomedics product candidates, technologies receive recognition from QTDP program

Editorial Focus eBook - Peptides and Oligonucleotides (2nd edition) eBook

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News